𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Estrogen-induced interaction between KLF5 and estrogen receptor (ER) suppresses the function of ER in ER-positive breast cancer cells

✍ Scribed by Peng Guo; Xue-Yuan Dong; Ke-Wen Zhao; Xiaodong Sun; Qunna Li; Jin-Tang Dong

Publisher
John Wiley and Sons
Year
2010
Tongue
French
Weight
368 KB
Volume
126
Category
Article
ISSN
0020-7136

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

Kruppel‐like factor 5 (KLF5) is implicated in human breast cancer by frequent genomic deletion and expressional deregulation, but the molecular mechanisms by which KLF5 affects breast tumorigenesis are still unknown. This study was conducted to examine whether and how KLF5 affects the function of estrogen receptor (ER) in breast cancer cells. Using different cell lines, we found that restored expression of KLF5 inhibited estrogen‐promoted cell proliferation in ER‐positive MCF‐7 and T‐47D cell lines but had no effect on ER‐negative SK‐BR‐3 cells. Transcriptional activity of ER was also suppressed by KLF5, as detected by using estrogen‐stimulated ER responsive element‐mediated reporter assay and expression analysis of ER target genes including c‐MYC and Cathepsin D (CSTD). Chromatin immunoprecipitation assays showed that KLF5 inhibited ERα binding to the promoter of c‐myc and CSTD. Furthermore, estrogen induced an interaction between KLF5 and ERα. These results suggest that KLF5 inhibits the function of ERα in gene regulation and cell proliferation through protein interaction that interrupts the binding of ERα to target gene promoters to prevent target gene induction.

📜 SIMILAR VOLUMES

Roscovitine, a selective CDK inhibitor,
Roscovitine, a selective CDK inhibitor, reduces the basal and estrogen-induced phosphorylation of ER-α in human ER-positive breast cancer cells
✍ Józefa Węsierska-Gądek; David Gritsch; Nora Zulehner; Oxana Komina; Margarita Ma 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 379 KB

## Abstract Roscovitine (ROSC), a selective cyclin‐dependent kinase (CDK) inhibitor, arrests human estrogen receptor‐α (ER‐α) positive MCF‐7 breast cancer cells in the G~2~ phase of the cell cycle and concomitantly induces apoptosis __via__ a p53‐dependent pathway. The effect of ROSC is markedly di

Analysis of the potential contribution o
Analysis of the potential contribution of estrogen receptor (ER) β in ER cytosolic assay of breast cancer
✍ J.P. Brouillet; M.A. Dujardin; D. Chalbos; J.M. Rey; J. Grenier; P.J. Lamy; T. M 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 French ⚖ 84 KB 👁 2 views

Estrogen receptor (ER) content is the most useful parameter for predicting hormone response therapy in breast cancer. Assays available for detecting ER in breast tumor cytosol are ligand-binding assay (LBA), which detects both ER␣ and ER␤, and the enzymatic immunoassay (EIA), in which monoclonal ant

Estrogen receptors (ER) in human breast
Estrogen receptors (ER) in human breast cancer. The significance of a new prognostic factor based on both ER protein and ER mRNA contents
✍ Marianne Gotteland; Evelyne May; Françoise May-Levin; Geneviève Contesso; Jean-C 📂 Article 📅 1994 🏛 John Wiley and Sons 🌐 English ⚖ 843 KB

Background. The response to endocrine therapy is not entirely predictable from the estrogen receptor (ER) and progesterone receptor (PgR) status of primary breast tumors. The authors previously proposed a new prognostic factor, ER.R, which was based on both ER protein and mRNA levels. A previous ana

Differential expression of estrogen rece
Differential expression of estrogen receptor alpha (ERα) protein in MCF-7 breast cancer cells chronically exposed to TCDD
✍ Lydia G. Marquez-Bravo; John F. Gierthy 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 268 KB

## Abstract Estrogens play a key role in the development and evolution of breast cancer tumors. Estrogen receptor alpha (ERα) mediates many of the biological activities of estrogens, and its expression is associated with low invasiveness and good prognosis. Recent epidemiological reports suggest th

Comparison of estrogen receptor determin
Comparison of estrogen receptor determinations by a biochemical ligand-binding assay and immunohistochemical staining with monoclonal antibody ER1D5 in females with lymph node positive breast carcinoma entered on two prospective clinical trials
✍ Steven R. Alberts; James N. Ingle; Patrick R. Roche; Stephen S. Cha; Lester E. W 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 830 KB

## BACKGROUND. The measurement of estrogen receptors (ER) in breast cancer specimens has traditionally been assessed with a tlextran-coated charcoal assay (DCCA). More recently the immunohistochemical staining (IHC) method has gained increasing popularity because of its ability to use fixed tissue